Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic ch

Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic ch

Item

http://www.wikidata.org/entity/Q36004950

Q36004950

about

Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.

P2860

Q26783229-1899E121-1717-4A75-9943-10B0C70E439E Q31061449-1CE83D7F-7FFA-4FD7-A8B0-BC24D2EAFD4B Q38650400-EE0E2AAD-76A6-4C5C-81D2-BFF5323F6FCE Q38904462-57B28DA4-877C-47BC-810A-A190FBF09F06 Q46355232-1A4F3755-3C49-464C-9247-062033D88DAF

P2860

Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic ch

Item

http://www.wikidata.org/entity/Q36004950

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Efficacy and safety of oral pa ...... tin-based highly emetogenic ch

@ast

Efficacy and safety of oral pa ...... tin-based highly emetogenic ch

@en

type

Item

label

Efficacy and safety of oral pa ...... tin-based highly emetogenic ch

@ast

Efficacy and safety of oral pa ...... tin-based highly emetogenic ch

@en

prefLabel

Efficacy and safety of oral pa ...... tin-based highly emetogenic ch

@ast

Efficacy and safety of oral pa ...... tin-based highly emetogenic ch

@en

P1476

Efficacy and safety of oral pa ...... tin-based highly emetogenic ch

@en

P2093

Alexander Filippov

http://www.w3.org/2001/XMLSchema#string

Csőszi Tibor

http://www.w3.org/2001/XMLSchema#string

Giada Rizzi

http://www.w3.org/2001/XMLSchema#string

Giorgia Rossi

http://www.w3.org/2001/XMLSchema#string

Maria Elisa Borroni

http://www.w3.org/2001/XMLSchema#string

Meinolf Karthaus

http://www.w3.org/2001/XMLSchema#string

Rajender Singh-Arora

http://www.w3.org/2001/XMLSchema#string

Steven M Grunberg

http://www.w3.org/2001/XMLSchema#string

Vito Lorusso

http://www.w3.org/2001/XMLSchema#string

P2860

Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.

The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.

Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy.

Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial

Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy.

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.

Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting.

On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993.

P2888

s00520-015-2657-1

P304

2917-2923

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00520-015-2657-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272945949

http://www.w3.org/2001/XMLSchema#string

P698

25724407

http://www.w3.org/2001/XMLSchema#string

P921

dexamethasone

P932

4552772

http://www.w3.org/2001/XMLSchema#string

Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic ch

about

P2860

P2860

Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic ch

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932